Literature DB >> 3459389

Imipenem pharmacokinetics and body fluid concentrations in patients receiving high-dose treatment for serious infections.

R R MacGregor, G A Gibson, J A Bland.   

Abstract

Serum, urine, tissue, and body fluids were collected from 40 adult patients who were receiving imipenem/cilastatin treatment for serious infections. Thirty-two patients were given 1 g every 6 h (4 g/day), and eight received 500 mg (2 g/day). Mean peak concentrations in serum were 34.9 +/- 4.0 micrograms/ml for the 1-g dose and 26.6 +/- 2.5 micrograms/ml for the 500-mg dose. Trough levels were 3.1 and 1.0 micrograms/ml, respectively. No evidence of drug accumulation was found after comparing peaks measured early in the treatment with those measured late. Peak levels were only marginally increased when infusions were given over 30 versus 60 min. The mean serum half-life was 82.0 +/- 25.3 min, with a range of 50 to 138 min. The apparent volume of distribution was 0.35 +/- 0.13 liter/kg, and the mean total body clearance was 0.183 +/- 0.067 liter/kg per h. Creatinine clearance correlated directly with the plasma elimination rate and inversely with the serum half-life. Moreover, total body clearance fell as the age of the patient rose. The mean urinary recovery was 39.1 +/- 12.8% (range, 15.0 to 59.2%) and did not correlate with creatinine clearance until it was below 15 ml/min. Of 20 specimens of various gastrointestinal secretions, 13 had imipenem concentrations that were low, but above the MIC for most resident flora. Pus, sputum, and bone all had concentrations of the drug sufficient to inhibit the infecting organisms, and these levels reflected generally excellent clinical responses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3459389      PMCID: PMC176375          DOI: 10.1128/AAC.29.2.188

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

2.  Effect of cefoperazone on faecal flora.

Authors:  K Alestig; H Carlberg; C E Nord; B Trollfors
Journal:  J Antimicrob Chemother       Date:  1983-08       Impact factor: 5.790

3.  A program for non-linear regression analysis to be used on desk-top computers.

Authors:  P Koeppe; C Hamann
Journal:  Comput Programs Biomed       Date:  1980-12

4.  Pharmacokinetics of imipenem in healthy volunteers.

Authors:  S R Norrby; B Björnegård; F Ferber; K H Jones
Journal:  J Antimicrob Chemother       Date:  1983-12       Impact factor: 5.790

5.  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

6.  Imipenem versus moxalactam in the treatment of serious infections.

Authors:  L J Eron; D L Hixon; C H Park; R I Goldenberg; D M Poretz
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

7.  Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients.

Authors:  B A Zajac; M A Fisher; G A Gibson; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

9.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

10.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

View more
  12 in total

1.  Imipenem concentrations in colorectal surgery and impact on the colonic microflora.

Authors:  L Kager; B Brismar; A S Malmborg; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Community Composition Determines Activity of Antibiotics against Multispecies Biofilms.

Authors:  Sarah Tavernier; Aurélie Crabbé; Mayram Hacioglu; Liesbeth Stuer; Silke Henry; Petra Rigole; Inne Dhondt; Tom Coenye
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

4.  Behavior of antibiotics during human necrotizing pancreatitis.

Authors:  C Bassi; P Pederzoli; S Vesentini; M Falconi; A Bonora; H Abbas; A Benini; E M Bertazzoni
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 5.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

6.  Activity of moxifloxacin, imipenem, and ertapenem against Escherichia coli, Enterobacter cloacae, Enterococcus faecalis, and Bacteroides fragilis in monocultures and mixed cultures in an in vitro pharmacokinetic/pharmacodynamic model simulating concentrations in the human pancreas.

Authors:  Sabine Schubert; Axel Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

Review 7.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

Review 8.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Biliary excretion of imipenem-cilastatin in hospitalized patients.

Authors:  A L Graziani; G A Gibson; R R MacGregor
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

10.  Pharmacokinetics and transplacental passage of imipenem during pregnancy.

Authors:  A Heikkilä; O V Renkonen; R Erkkola
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.